Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * ECOG performance status \< 2 * Patients must have a confirmed diagnosis of multiple myeloma and have received 1-3 prior lines of therapy and must be: * Exposed to a proteasome inhibitor, IMiD, and anti-CD38 antibody prior to enrollment. Patients must have measurable evidence of multiple myeloma defined as one of the following: * Serum M protein ≥ 0.5 g/dL * Abnormal free light chain ratio, provided involved light chain is \>10mg/dL * Urine M protein ≥ 200 mg/24 hours * Hematologic laboratory parameters of: * Absolute neutrophil count (ANC) \> 1,000/mm3 * Hemoglobin \> 8g/dL * Platelet count \> 75,000/μL if plasma cells account for \< 50% bone marrow * Nucleated cells and \> 50,000/μL if plasma cells account for \> 50% of bone marrow nucleated cells * Non-hematologic laboratory parameters of: * Total Bilirubin of \< 2 times the upper limit of normal * ALT and AST \< 3 times the upper limit of normal * Corrected serum calcium \>13 mg/dL * Est…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source